Heartflow stock rating reiterated at Buy by Canaccord on IP suit

Canaccord reiterated a Buy rating on Heartflow with a $43 price target versus the current $26.93 share price, implying meaningful upside. The firm cited 40% revenue growth, a 76.8% gross margin, and a Q4 revenue beat at $49.1 million versus $46.6 million consensus. The main overhang is Heartflow’s patent infringement lawsuit against Cleerly, which could pressure Cleerly’s funding efforts but is not expected to materially change Heartflow’s cost outlook.

Analysis

The real market issue here is not the litigation headline itself but the asymmetry between Heartflow’s public-market multiple and Cleerly’s private-market financing window. If management can credibly use IP as a moat, the stock can re-rate on a cleaner path to share capture; if the case drags, the overhang is less about legal expense and more about whether the addressable market becomes a two-horse race with one participant capital-constrained. In that scenario, the competitive damage is forward-loaded: hospitals and payers may delay vendor adoption decisions until ownership of the core workflow is clearer.

Second-order, the biggest beneficiary may be not Heartflow alone but the broader category of AI-assisted cardiac diagnostics, because a high-profile IP case forces buyers to standardize on the vendor with the most defensible regulatory and legal position. That should favor incumbents with deeper reimbursement integration and existing enterprise relationships, while pressuring any late-stage private rival that still needs another financing round to fund commercialization. The financing angle matters: if Cleerly cannot close capital quickly, commercialization timelines extend by quarters, which can turn a patent dispute into a distribution bottleneck rather than a courtroom issue.

The risk is that this becomes a classic “win the case, lose the narrative” setup. Even with a strong balance sheet, prolonged discovery can keep a lid on valuation for months, and any adverse procedural ruling could reset upside by making the moat story less credible. The contrarian read is that the market may be underestimating how much of Heartflow’s value is tied to category trust rather than just growth, which means the stock can stay supported even if the litigation itself produces no immediate monetary award.

Key Decisions for Investors

• Long HTFL vs short a basket of earlier-stage medtech AI/private peers exposed to commercialization capital needs for 3-6 months; the spread should widen if the litigation slows Cleerly fundraising and customer adoption.
• Buy HTFL on pullbacks only after volatility spikes, targeting a 4-8 week horizon; risk/reward improves if implied legal uncertainty compresses the stock while fundamentals stay intact.
• Avoid initiating a short in HTFL here: the cleaner trade is to short the weaker funding-dependent competitor indirectly, since HTFL’s litigation may actually reinforce moat perception over a 1-2 quarter horizon.
• If accessible, consider call spreads on HTFL with 2-3 month tenor; upside is driven by a re-rating on moat durability, while downside is cushioned by already-strong operating momentum.
• Monitor private-market funding signals for Cleerly over the next 30-60 days; a failed capital raise is the highest-conviction catalyst for HTFL outperformance.